FDA warns Imu-Tek Animal Health over unapproved drug claims and manufacturing failures for Colostrom-5 products.
What happened
FDA inspected the Fort Collins, CO facility from October 6 through October 14, 2025, and reviewed www.imutek.com in April 2026. The inspection found current good manufacturing practice (CGMP) failures for dietary supplements, including pasteurization deviations, no component or finished-product specifications, and no written master manufacturing record. The website claimed Colostrom-5 Capsules and Powder "kill bacteria and viral invaders" and help correct bowel dysfunction, making them unapproved new drugs and misbranded drugs.
What FDA found
Website claims that Colostrom-5 Capsules and Powder kill bacteria and viral invaders and help correct bowel dysfunction make them drugs intended to treat disease, but FDA has not approved them as new drugs.
21 U.S.C. 321(g)(1)(B), 321(p), 331(d), 355(a)The products are misbranded because they are intended for diseases that laypeople cannot safely diagnose or treat without a licensed practitioner, so they lack adequate directions for use.
21 U.S.C. 352(f)(1); 21 CFR 201.5Quality control did not reject or approve the colostrum when pasteurization temperatures and hold times deviated from the company's procedure, and the colostrum was still used.
21 CFR 111.113(b)(1)The company had not established component specifications for identity, purity, strength, composition, or contamination limits, and had not established finished-product specifications.
21 CFR 111.70(b), 111.70(e); 111.73; 111.75The company did not have a written master manufacturing record for Colostrom-5 Capsules or Powder to ensure batch-to-batch uniformity.
21 CFR 111.205(a); 111.210Batch production records for Colostrom-5 were missing required information such as component identifiers and weights, test results, finished-product specification documentation, packaging and labeling records, and quality control approval or rejection.
21 CFR 111.260
What FDA wants
FDA asks Imu-Tek to notify it in writing within 15 working days of receipt of the letter about specific steps taken to address the violations and prevent recurrence, with related documentation. If corrective actions cannot be completed within 15 working days, the company must state the reason for delay and when it will finish.
Who should pay attention
- animal health brands selling colostrum or immune-claim supplements
- contract manufacturers and labelers of dietary supplements
- retailers and distributors of animal supplements
This is a summary. Read the original letter on fda.gov.